Drug intelligence / Profile preview

MaxMist

Development stage
Unknown
Lead developer
Bennett Pharmaceuticals of America
Modality
Small Molecules
Administration
Intranasal
01

Overview

**MaxMist** is a ready-to-use, single-use intranasal anesthetic spray manufactured by Bennett Pharmaceuticals for needle-free local anesthesia. The dental formulation contains tetracaine hydrochloride, bupivacaine hydrochloride, and phenylephrine hydrochloride and is intended to produce anterior superior alveolar and middle superior alveolar nerve block for pulpal anesthesia of teeth 5–12; the product is also positioned for intranasal anesthesia before ENT procedures. Tetracaine and bupivacaine provide local anesthesia through reversible blockade of voltage-gated sodium channels, while phenylephrine produces alpha-1 adrenergic vasoconstriction that can limit local blood flow and prolong anesthetic effect. ([shop.bennett-pharma.com](https://shop.bennett-pharma.com/products/maxmist-intranasal-anesthetic-short-date))

Brand names
MaxMist
Other names
MaxMist DentalMaxMist Dental Delivery SystemMaxMist nasal spray
02

Targets

NaV (Voltage-gated sodium channels)ADRA1A (α1A)

Beyond the preview

Go deeper on MaxMist.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MaxMist.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call